These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29237991)

  • 1. Survival of HeartMate II Patients Despite Cessation of Anticoagulation　- Outcomes and Hemostatic Analysis.
    Zayat R; Khattab MA; Grottke O; Honickel M; Goetzenich A; Moza A; Stoppe C; Autschbach R; Tewarie L
    Circ J; 2018 Apr; 82(5):1309-1318. PubMed ID: 29237991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
    Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative onset of acquired von Willebrand syndrome: Comparison between HVAD, HeartMate II and on-pump coronary bypass surgery.
    Feldmann C; Zayat R; Goetzenich A; Aljalloud A; Woelke E; Maas J; Tewarie L; Schmitz-Rode T; Autschbach R; Steinseifer U; Moza A
    PLoS One; 2017; 12(2):e0171029. PubMed ID: 28234916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices.
    Birschmann I; Dittrich M; Eller T; Wiegmann B; Reininger AJ; Budde U; Strüber M
    J Heart Lung Transplant; 2014 Jan; 33(1):80-7. PubMed ID: 24418734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
    Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
    J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
    Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
    J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients.
    Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Trummer G; Berchtold-Herz M; Schlensak C; Zieger B
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1328-33; discussion 1233. PubMed ID: 21515067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients With Ventricular Assist Devices.
    Geisen U; Brehm K; Trummer G; Berchtold-Herz M; Heilmann C; Beyersdorf F; Schelling J; Schlagenhauf A; Zieger B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29331958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center.
    Esmaeilzadeh F; Wauters A; Wijns W; Argacha JF; van de Borne P
    BMC Cardiovasc Disord; 2016 Aug; 16(1):155. PubMed ID: 27485105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices.
    Baghai M; Heilmann C; Beyersdorf F; Nakamura L; Geisen U; Olschewski M; Zieger B
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):421-7. PubMed ID: 25543177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.
    Crow S; Chen D; Milano C; Thomas W; Joyce L; Piacentino V; Sharma R; Wu J; Arepally G; Bowles D; Rogers J; Villamizar-Ortiz N
    Ann Thorac Surg; 2010 Oct; 90(4):1263-9; discussion 1269. PubMed ID: 20868825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired von Willebrand factor deficiency is reduced in HeartMate 3 patients†.
    Klaeske K; Dieterlen MT; Scholz U; Lehmann S; Garbade J; Fischer J; Jawad K; Borger MA; Meyer A
    Eur J Cardiothorac Surg; 2019 Sep; 56(3):444-450. PubMed ID: 30815698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.
    Uriel N; Pak SW; Jorde UP; Jude B; Susen S; Vincentelli A; Ennezat PV; Cappleman S; Naka Y; Mancini D
    J Am Coll Cardiol; 2010 Oct; 56(15):1207-13. PubMed ID: 20598466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
    Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are elevated serum haemolysis markers a harbinger of adverse events in HeartMate II patients?
    Zayat R; Shoaib M; Khattab MA; Ahmad U; Goetzenich A; Stoppe C; Foldenauer AC; Moza A; Schnoering H; Autschbach R; Tewarie L
    Interact Cardiovasc Thorac Surg; 2018 Jul; 27(1):5-12. PubMed ID: 29444250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.
    Terrovitis JV; Ntalianis A; Kapelios CJ; Vakrou S; Diakos N; Katsaros L; Tsamatsoulis M; Kaldara E; Charitos C; Nanas JN
    Hellenic J Cardiol; 2015; 56(1):20-5. PubMed ID: 25701968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.